Short answer
OMEROS CORP (OMER) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $29M with net income of $13M.
Q2 2026 key financials · XBRL
- Revenue
- $29M
- +188.4% QoQ
- Net income
- $13M
- +152.0% YoY · −76.4% QoQ
- Operating margin
- 0.3%
- EPS (diluted)
- $0.15
- +134.9% YoY · −75.8% QoQ
Source: XBRL data from the OMEROS CORP (OMER) Q2 2026 10-Q on SEC EDGAR. USD.
OMEROS CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product sales $28.5M vs $0 YoY, reflecting YARTEMLEA launch and physician adoption
- Gross margin 97.2%, based on $28.5M revenue and $0.8M product costs
- R&D expense $13.8M vs $22.0M YoY; SG&A $13.9M vs $10.3M
- Cash, equivalents and short-term investments $132.0M; operating cash flow $4.1M
- Q3 R&D and SG&A expected higher, driven by YARTEMLEA and OncotoX-AML investment
Risk Factors
- Newly added risk: $100.0 million share-repurchase program authorized in November 2025
- Most material update: 488,716 shares repurchased at $11.70 average during the quarter
- Market risk: Repurchases could increase volatility, reduce liquidity, or precede stock-price declines
- Regulatory risk: Program suspension or termination remains subject to corporate and regulatory requirements
- Financial risk: $90.1 million remained available for future repurchases as of August 12, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OMEROS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.